DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
spry - 1 There's - 1 Jim Watson - 1 Coke - 1 Watson - 1 Ramon Laguarta - 1 influencer Logan - 1 Mike Del Pozzo - 1
Top related locs:
London Britain U.S
Top related orgs:
Unilever - 2 Gatorade - 1 Euromonitor - 1 Cola - 1 Pepsi - 1 Rabobank - 1 Nestle Health Science - 1 PepsiCo - 1

Search resuls for: "Nestle Health Science"


3 mentions found


☆ Gatorade enters new categories — even unflavored water — as competition to hydrate consumers ramps up
  + stars: | 2024-04-06 | by ( Amelia Lucas | ) www.cnbc.com   time to read: +5 min
As Gatorade approaches its 60th birthday, the brand is staying spry, branching out into new categories from unflavored water to energy drink mixes. It accounted for 63.5% of the U.S. sports drink market in 2023, according to Euromonitor International data. Gatorade President Mike Del Pozzo told CNBC that the competition is good for the category overall – and shows his brand's own strength. "There's plenty of loud voices right now, trying to make a name for themselves," said Del Pozzo. And Propel's annual sales are projected to cross $1 billion for the first time this year, Del Pozzo said.
Persons: spry, There's, Jim Watson, Coke, Watson, Ramon Laguarta, influencer Logan, Mike Del Pozzo, Del Pozzo, we're, Rabobank's Watson Organizations: Gatorade, Euromonitor, Cola, Pepsi, Rabobank, Unilever, Nestle Health Science, PepsiCo, Energy, Citi Research, CNBC
☆ Nestle shares at two-year low as investors weigh Wegovy rollout
  + stars: | 2023-10-06 | by ( ) www.reuters.com   time to read: +2 min
REUTERS/Hannah McKay/Photo Illustration/File Photo Acquire Licensing RightsOct 6 (Reuters) - Nestle (NESN.S) shares were under pressure on Friday as investors weighed the potential impact of Novo Nordisk's (NOVOb.CO) blockbuster weight-losing drug Wegovy and how it could reduce spending on food. The KitKat and Nescafe coffee maker's shares were down 2% and headed for their lowest level in more than two years. However, Cox does not regard this as a substantial risk to Nestle and the broader food industry in the long term. Bruno Monteyne from Bernstein also pointed to the Wegovy impact, but saw little logic in the sell-off. "Danone sells water, baby milk powder, and yogurt: not sure how those would be negatively impacted by GLP1 / Wegovy?"
Persons: Kat, Hannah McKay, Wegovy, Peers, Kepler Cheuvreux, Jon Cox, John Furner, Cox, Bruno Monteyne, Bernstein, Andrey Sychev, John Revill, Mark Potter Organizations: Nestle, REUTERS, Peers Danone, Unilever, Kepler, Bloomberg, Danone, Health, Thomson Locations: London, Britain, U.S
☆ This biotech stock is up 10% in the last month — and analysts expect it to rise a further 118%
  + stars: | 2023-01-19 | by ( Ganesh Rao | ) www.cnbc.com   time to read: +2 min
Wall Street is bullish on the California-headquartered company, which makes the enzymes for Pfizer's Covid-19 oral antiviral treatment ; all eight equity analysts covering the stock give it a buy rating. Their median price target points to a 118% potential upside over the 12 months, according to FactSet. "We believe that PRGN's R & D event will validate the key value propositions that underscore PRGN-2012," said Cantor Fitzgerald's analysts in a note to clients on Jan. 12. Other companies on the list include the London-listed stock of Oxford Nanopore Technologies and Genus , which analysts expect to rise by more than 40% over the next 12 months. Clinical diagnostics company Bio-Rad Lab and Sweden-headquartered IVF specialist Vitrolife are the other stocks expected to go up by analysts.
0 next >>
Total: 3